240 related articles for article (PubMed ID: 26434717)
41. Reynosin protects against neuronal toxicity in dopamine-induced SH-SY5Y cells and 6-hydroxydopamine-lesioned rats as models of Parkinson's disease: Reciprocal up-regulation of E6-AP and down-regulation of α-synuclein.
Ham A; Kim DW; Kim KH; Lee SJ; Oh KB; Shin J; Mar W
Brain Res; 2013 Aug; 1524():54-61. PubMed ID: 23751361
[TBL] [Abstract][Full Text] [Related]
42. Methamphetamine binds to α-synuclein and causes a conformational change which can be detected by nanopore analysis.
Tavassoly O; Lee JS
FEBS Lett; 2012 Sep; 586(19):3222-8. PubMed ID: 22771474
[TBL] [Abstract][Full Text] [Related]
43. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
44. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
45. DEAD-box RNA helicase Dbp4/DDX10 is an enhancer of α-synuclein toxicity and oligomerization.
Popova B; Wang D; Pätz C; Akkermann D; Lázaro DF; Galka D; Kolog Gulko M; Bohnsack MT; Möbius W; Bohnsack KE; Outeiro TF; Braus GH
PLoS Genet; 2021 Mar; 17(3):e1009407. PubMed ID: 33657088
[TBL] [Abstract][Full Text] [Related]
46. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.
Azeredo da Silveira S; Schneider BL; Cifuentes-Diaz C; Sage D; Abbas-Terki T; Iwatsubo T; Unser M; Aebischer P
Hum Mol Genet; 2009 Mar; 18(5):872-87. PubMed ID: 19074459
[TBL] [Abstract][Full Text] [Related]
47. The Cytotoxic Effect of α-Synuclein Aggregates.
Melo F; Caballero L; Zamorano E; Ventura N; Navarro C; Doll I; Zamorano P; Cornejo A
Chemphyschem; 2021 Mar; 22(6):526-532. PubMed ID: 33482036
[TBL] [Abstract][Full Text] [Related]
48. Structural insights on physiological functions and pathological effects of alpha-synuclein.
Bisaglia M; Mammi S; Bubacco L
FASEB J; 2009 Feb; 23(2):329-40. PubMed ID: 18948383
[TBL] [Abstract][Full Text] [Related]
49. Increased oligomerization and phosphorylation of α-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains.
Liu G; Chen M; Mi N; Yang W; Li X; Wang P; Yin N; Li Y; Yue F; Chan P; Yu S
Neurobiol Aging; 2015 Sep; 36(9):2649-59. PubMed ID: 26149921
[TBL] [Abstract][Full Text] [Related]
50. Fibril growth and seeding capacity play key roles in α-synuclein-mediated apoptotic cell death.
Mahul-Mellier AL; Vercruysse F; Maco B; Ait-Bouziad N; De Roo M; Muller D; Lashuel HA
Cell Death Differ; 2015 Dec; 22(12):2107-22. PubMed ID: 26138444
[TBL] [Abstract][Full Text] [Related]
51. Alpha-synuclein aggregation variable temperature and variable pH kinetic data: a re-analysis using the Finke-Watzky 2-step model of nucleation and autocatalytic growth.
Morris AM; Finke RG
Biophys Chem; 2009 Mar; 140(1-3):9-15. PubMed ID: 19101068
[TBL] [Abstract][Full Text] [Related]
52. Oxidation and nitration of α-synuclein and their implications in neurodegenerative diseases.
Chavarría C; Souza JM
Arch Biochem Biophys; 2013 May; 533(1-2):25-32. PubMed ID: 23454347
[TBL] [Abstract][Full Text] [Related]
53. Characterizing the inhibition of α-synuclein oligomerization by a pharmacological chaperone that prevents prion formation by the protein PrP.
Dong C; Garen CR; Mercier P; Petersen NO; Woodside MT
Protein Sci; 2019 Sep; 28(9):1690-1702. PubMed ID: 31306510
[TBL] [Abstract][Full Text] [Related]
54. Fluorescent ratiometric MFC probe sensitive to early stages of alpha-synuclein aggregation.
Yushchenko DA; Fauerbach JA; Thirunavukkuarasu S; Jares-Erijman EA; Jovin TM
J Am Chem Soc; 2010 Jun; 132(23):7860-1. PubMed ID: 20491471
[TBL] [Abstract][Full Text] [Related]
55. Alpha-synuclein and its role in metal binding: relevance to Parkinson's disease.
Wright JA; Brown DR
J Neurosci Res; 2008 Feb; 86(3):496-503. PubMed ID: 17705291
[TBL] [Abstract][Full Text] [Related]
56. Changes in the cellular fatty acid profile drive the proteasomal degradation of α-synuclein and enhance neuronal survival.
Xylaki M; Boumpoureka I; Kokotou MG; Marras T; Papadimitriou G; Kloukina I; Magrioti V; Kokotos G; Vekrellis K; Emmanouilidou E
FASEB J; 2020 Nov; 34(11):15123-15145. PubMed ID: 32931072
[TBL] [Abstract][Full Text] [Related]
57. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity.
Kontopoulos E; Parvin JD; Feany MB
Hum Mol Genet; 2006 Oct; 15(20):3012-23. PubMed ID: 16959795
[TBL] [Abstract][Full Text] [Related]
58. Understanding Caffeine's Role in Attenuating the Toxicity of α-Synuclein Aggregates: Implications for Risk of Parkinson's Disease.
Kardani J; Roy I
ACS Chem Neurosci; 2015 Sep; 6(9):1613-25. PubMed ID: 26167732
[TBL] [Abstract][Full Text] [Related]
59. α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation.
Burré J; Sharma M; Südhof TC
Proc Natl Acad Sci U S A; 2014 Oct; 111(40):E4274-83. PubMed ID: 25246573
[TBL] [Abstract][Full Text] [Related]
60. Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging.
Klucken J; Outeiro TF; Nguyen P; McLean PJ; Hyman BT
FASEB J; 2006 Oct; 20(12):2050-7. PubMed ID: 17012257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
